MA27935A1 - Modifications stables du maleate d'hydrogene tegaserod - Google Patents

Modifications stables du maleate d'hydrogene tegaserod

Info

Publication number
MA27935A1
MA27935A1 MA28759A MA28759A MA27935A1 MA 27935 A1 MA27935 A1 MA 27935A1 MA 28759 A MA28759 A MA 28759A MA 28759 A MA28759 A MA 28759A MA 27935 A1 MA27935 A1 MA 27935A1
Authority
MA
Morocco
Prior art keywords
hydrogen maleate
tegaserod hydrogen
stable modifications
tegaserod
stable
Prior art date
Application number
MA28759A
Other languages
English (en)
Inventor
Sabine Pfeffer
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27935(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27935A1 publication Critical patent/MA27935A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Cette invention se rapporte à des formes cristallines du maléate d'hydrogène tegaserod, à leur utilisation dans des compositions pharmaceutiques servant au traitement du syndrome du côlon irritable, du reflux gastrooesophagien pathologique, de la dyspepsie fonctionnelle, et de la constipation ou de la diarrhée chroniques, ainsi qu'à leur production.
MA28759A 2003-07-24 2006-01-27 Modifications stables du maleate d'hydrogene tegaserod MA27935A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48963803P 2003-07-24 2003-07-24

Publications (1)

Publication Number Publication Date
MA27935A1 true MA27935A1 (fr) 2006-06-01

Family

ID=34135099

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28759A MA27935A1 (fr) 2003-07-24 2006-01-27 Modifications stables du maleate d'hydrogene tegaserod

Country Status (24)

Country Link
US (1) US20070112056A1 (fr)
EP (2) EP1651601A1 (fr)
JP (1) JP2006528609A (fr)
KR (1) KR20060040710A (fr)
CN (1) CN1826318A (fr)
AR (1) AR045081A1 (fr)
AU (1) AU2004263285A1 (fr)
BR (1) BRPI0412830A (fr)
CA (1) CA2532351A1 (fr)
CO (1) CO5680418A2 (fr)
EC (1) ECSP066306A (fr)
IL (1) IL172914A0 (fr)
IS (1) IS8321A (fr)
MA (1) MA27935A1 (fr)
MX (1) MXPA06000917A (fr)
MY (1) MY137386A (fr)
NO (1) NO20060915L (fr)
NZ (1) NZ544596A (fr)
PE (1) PE20050253A1 (fr)
RU (1) RU2349585C2 (fr)
SG (1) SG144944A1 (fr)
TN (1) TNSN06024A1 (fr)
TW (1) TW200510302A (fr)
WO (1) WO2005014544A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723106A2 (fr) * 2004-10-19 2006-11-22 Teva Pharmaceutical Industries Ltd. Purification du maleate de tegaserod
EP1853256A2 (fr) * 2005-01-31 2007-11-14 Novartis AG Composes organiques
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
KR20070062504A (ko) * 2005-06-22 2007-06-15 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 말레이트의 다형태
AR058078A1 (es) * 2005-10-06 2008-01-23 Medichem Sa Maleato de tegaserod y procesos de obtencion
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120924A1 (fr) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Préparation de maléate de tegaserod exempt de iodure
EP1956002A1 (fr) * 2007-02-07 2008-08-13 Chemo Ibérica, S.A. Nouveaux polymorphes de maléate de tégasérod et leur procédé de préparation
EP2146958A1 (fr) * 2007-05-17 2010-01-27 Generics Ýuk¨Limited Procédé de préparation de la forme a du tégasérode

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242588A (ja) * 1988-03-25 1989-09-27 Chiba Gosei Kenkyusho:Kk ７―シアノメチルチオアセトアミド―７α―メトキシ―３―（１―メチル―１Ｈ―テトラゾール―５―イル）チオメチル―３―セフェム―４―カルボン酸の結晶及びその製造方法
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
GB9106179D0 (en) * 1991-03-22 1991-05-08 Sandoz Ltd Improvements in or relating to organic compounds
JPH08291140A (ja) * 1995-04-20 1996-11-05 Teikoku Chem Ind Corp Ltd 易吸収性結晶
ID28510A (id) * 1998-08-21 2001-05-31 Novartis Ag Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
EP1321142A1 (fr) * 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
CN1176077C (zh) * 2003-01-07 2004-11-17 江苏省药物研究所 马来酸替加色罗一水结晶
WO2004085393A1 (fr) * 2003-03-25 2004-10-07 Hetero Drugs Limited Nouvelles formes cristallines de maleate de tegaserod
EP1594493A2 (fr) * 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Formes polymorphiques de la base du tegaserod et des sels de celui-ci
US20050272802A1 (en) * 2004-04-22 2005-12-08 Sundaram Venkataraman Process for preparing form I of tegaserod maleate
KR20070062504A (ko) * 2005-06-22 2007-06-15 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 말레이트의 다형태

Also Published As

Publication number Publication date
RU2349585C2 (ru) 2009-03-20
TW200510302A (en) 2005-03-16
CO5680418A2 (es) 2006-09-29
MY137386A (en) 2009-01-30
CA2532351A1 (fr) 2005-02-17
AR045081A1 (es) 2005-10-12
ECSP066306A (es) 2006-07-28
BRPI0412830A (pt) 2006-09-26
RU2006105481A (ru) 2007-09-20
IS8321A (is) 2006-02-22
EP1651601A1 (fr) 2006-05-03
MXPA06000917A (es) 2006-03-30
US20070112056A1 (en) 2007-05-17
AU2004263285A1 (en) 2005-02-17
WO2005014544A1 (fr) 2005-02-17
PE20050253A1 (es) 2005-06-03
EP1880992A1 (fr) 2008-01-23
NZ544596A (en) 2009-01-31
IL172914A0 (en) 2006-06-11
KR20060040710A (ko) 2006-05-10
JP2006528609A (ja) 2006-12-21
SG144944A1 (en) 2008-08-28
CN1826318A (zh) 2006-08-30
NO20060915L (no) 2006-04-24
TNSN06024A1 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA30558B1 (fr) Antagonistes de recepteurs cgrp monocycliques substitues
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
EP1641423A4 (fr) Antagonistes du recepteur du cgrp de
BRPI0410905A (pt) inibidores de p-38
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
SE0403006D0 (sv) New compounds
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA28111A1 (fr) Derives des
SE0104331D0 (sv) Novel compounds
MY133845A (en) Il-8 receptor antagonists
WO2005000231A3 (fr) Antagonistes du recepteur il-8
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
AP1548A (en) Il-8 Receptor Antagonists.
NZ514696A (en) IL-8 receptor antagonists
MX2007001990A (es) Antagonistas del receptor 5-ht7.
MY137386A (en) Stable modifications of tegaserod hydrogen maleate
AP2002002606A0 (fr) Antagonistes du recepteur de l'interleukine 8
MY143477A (en) Il-8 receptor antagonists
MA29694B1 (fr) Derives de l'imidazopyridine comme ligands du recepteur cannabinoide
TW200504036A (en) Novel lactams and uses thereof
WO2005035504A3 (fr) Antagonistes selectifs des recepteurs d1/d5 utilises dans le traitement de l'obesite et des troubles du systeme nerveux central
WO2001068033A3 (fr) Antagonistes du recepteur de il-8